fig1

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression

Figure 1. Ras/MAPK activity is inversely related to STAT activation in murine mammary cancer cell lines. A: immunoblot analysis of MMTV-Neu cells treated with or without trametinib (50 nM; MEKi) for 24 or 48 h prior to lysis; B: MMTV-Neu cells stably expressing LacZ or constitutively active MEKDD were treated and analyzed as in A; C: 4T1, EMT6, and E0771 murine mammary cells were treated and analyzed as in A. MAPK: mitogen activated protein kinase; MEKi: MEK inhibition

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/